Literature DB >> 27155764

Cell-Penetrating Peptide Penetratin as a Potential Tool for Developing Effective Nasal Vaccination Systems.

Keiya Muto1, Noriyasu Kamei2, Mia Yoshida1, Kozo Takayama1, Mariko Takeda-Morishita3.   

Abstract

Nasal vaccination is considered an attractive strategy to prevent the infection and spread of viruses. However, the vaccine formulations available on the market remain imperfect on account of their limited effectiveness. In the present study, we hypothesized that the nasal coadministration of antigens with cell-penetrating peptides promotes antigen delivery immune response in the nasal mucosa, thereby enhancing the production of mucosal IgA and systemic IgG. The levels of ovalbumin (OVA)-specific IgG and IgA in plasma and nasal perfusate, respectively, increased after 2 or 4 weeks on nasal coadministration of OVA with l- or d-penetratin, suggesting that OVA antigen was effectively delivered by penetratin to the nasal epithelium. An additional study demonstrated that the production of systemic IgG and nasal mucosal IgA against influenza A virus was specifically promoted by nasal coadministration of influenza A virus with d-penetratin. The results of this study suggested that cell-penetrating peptides are a promising tool for the delivery of vaccines to the nasal mucosa and for the subsequent dual stimulation of systemic and mucosal immune responses.
Copyright © 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  mucosal immunization; mucosal vaccination; nasal drug delivery; protein delivery; vaccine delivery

Mesh:

Substances:

Year:  2016        PMID: 27155764     DOI: 10.1016/j.xphs.2016.03.026

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

Review 1.  Peptide-Based Vaccines for Tuberculosis.

Authors:  Wenping Gong; Chao Pan; Peng Cheng; Jie Wang; Guangyu Zhao; Xueqiong Wu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

2.  Antiviral cyclic peptides targeting the main protease of SARS-CoV-2.

Authors:  Jason Johansen-Leete; Sven Ullrich; Sarah E Fry; Rebecca Frkic; Max J Bedding; Anupriya Aggarwal; Anneliese S Ashhurst; Kasuni B Ekanayake; Mithun C Mahawaththa; Vishnu M Sasi; Stephanie Luedtke; Daniel J Ford; Anthony J O'Donoghue; Toby Passioura; Mark Larance; Gottfried Otting; Stuart Turville; Colin J Jackson; Christoph Nitsche; Richard J Payne
Journal:  Chem Sci       Date:  2022-02-28       Impact factor: 9.825

Review 3.  Protein transduction domain of translationally controlled tumor protein: characterization and application in drug delivery.

Authors:  Jeehye Maeng; Kyunglim Lee
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 4.  Overcoming the cellular barriers and beyond: Recent progress on cell penetrating peptide modified nanomedicine in combating physiological and pathological barriers.

Authors:  Yingke Liu; Zhihe Zhao; Man Li
Journal:  Asian J Pharm Sci       Date:  2022-06-23       Impact factor: 9.273

5.  Cell-Penetrating Peptides-Based Liposomal Delivery System Enhanced Immunogenicity of Peptide-Based Vaccine against Group A Streptococcus.

Authors:  Jieru Yang; Farrhana Firdaus; Armira Azuar; Zeinab G Khalil; Nirmal Marasini; Robert J Capon; Waleed M Hussein; Istvan Toth; Mariusz Skwarczynski
Journal:  Vaccines (Basel)       Date:  2021-05-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.